Combining Vitamin D3 and Retinoids to Fight Prostate Cancer
Author Information
Author(s): Campbell M J, Park S, Uskokovic M R, Dawson M I, Jong L, Koeffler H P
Primary Institution: Cedars-Sinai Medical Center, UCLA School of Medicine
Hypothesis
Can a combination of a vitamin D3 analogue and an anti-activator protein 1 retinoid synergistically inhibit prostate cancer cell growth?
Conclusion
The combination of the vitamin D3 analogue and the anti-AP-1 retinoid can synergistically inhibit the growth of certain prostate cancer cell lines.
Supporting Evidence
- The combination of LH and SR11238 inhibited the growth of LNCaP and PC-3 prostate cancer cell lines.
- SR11238 alone was inactive against these cell lines.
- LNCaP cells underwent apoptosis when treated with both compounds.
Takeaway
Using two special medicines together can help stop some prostate cancer cells from growing better than using them alone.
Methodology
The study tested the effects of a vitamin D3 analogue and an anti-AP-1 retinoid on various prostate cancer cell lines.
Limitations
The study only tested a limited number of prostate cancer cell lines and did not explore the effects on all types of prostate cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website